Senior-Level Finance Executive eager to contribute extensive talents and outstanding academic credentials toward supporting a dynamic organization in optimizing bottom-line performance.

 

 

• Significant experience in planning, coordinating, directing and evaluating full-scope financial operations related to corporate alliances, acquisitions, in-licensing, and portfolio governance.
• Extremely versatile and able to quickly adapt to new roles, environments, tasks, and responsibilities.
• Confident and proactive with exceptional skills in delivering presentations to top-level executives.
• Able to effectively scrutinize and evaluate opportunities for profitability and financial risk.
• Adept at performing complex financial analysis to support strategic plans and operating budgets.
• Proficiency in reporting, budget administration, forecasting, and capturing substantial cost savings.
• Excellent ability to establish cooperative working relationships with all levels of an organization, and regarded as a natural leader.

 

 

Schering-Plough Corporation Kenilworth, NJ, 2001 to Present

Finance Director / Senior Finance Director (2008 to Present)

         Spearhead Merck integration planning, seamlessly coordinating activities across multiple teams at both companies representing a combined value of $41B.

         Assembled and co-facilitated Schering-Plough Value Creation Summit to identify growth opportunities for combined company.

         Championed creation and provision of Schering-Plough financial baseline information and sharing past practices related to savings tracking and reporting.

         Proactively partnered with executive management at Merck & Schering-Plough to precisely establish framework for Schering-Plough integration team.

         Teamed with Corporate Controller and Executive Management in directing Productivity Transformation Program to elevate productivity and slash costs by $1.5B annually.

         Applied sharp analytical strengths toward systematically devising tools to track and report headcount and cost savings, closely collaborating with Global Human Resources and senior management to optimize outcome of headcount reduction initiative.

         As member of HR Leadership Team, diligently monitor and document key HR metrics associated with program.

 

Finance Director, Business Development (2006 to 2008)

         Strategically provided extensive financial valuation and analysis of business development opportunities in human pharmaceuticals and animal health sectors.

         Oversaw $14.4B acquisition of Organon BioSciences and served as Finance Lead for Integrating Planning Team, expertly providing strategic financial support to corporate leadership to achieve synergy targets consistent with transaction strategy.

         Administered worldwide agreement with Aveo Pharmaceuticals Inc. for development and commercialization of an oncology antibody with potential payments of $450M+.

         Finalized global agreement with Novacea, Inc. for development and commercialization of a Phase III candidate for prostate cancer representing potential payments of $400M+.

         Supported Corporate Controller in directing cross-functional team in governance of value realization.

 

Continued ►

 

 

 

Professional Experience continued Yyyyyy x. yyyyyy, Page 2 of 2

 

         Strategically revised corporate policy to streamline and standardize business development transactions.

         Resourcefully created and instituted electronic workflow solution for human resources to enhance efficiency, and collaborated with HR department in headcount reduction efforts.

         Overhauled and improved approach used to assess pre-clinical licensing opportunities,

         Produced comprehensive due diligence field guide covering all aspects of corporate diligence on potential acquisition candidates.

 

Finance Director, Schering-Plough Research Institute [SPRI] (2005 to 2006)

         Proficiently provided effective strategic and financial analysis for $17.5M acquisition of NeoGenesis Pharmaceuticals, Inc. and orchestrated smooth operational integration.

         Led staff of seven in management of $400M operating budget for several SPRI organizations.

         Navigated SPRI Value Enhancement Initiative supporting Executive VP of Pre-Clinical Development.

         Efficiently handled fiscal elements of several strategic expansion opportunities including occupancy of a newly-constructed toxicology facility and a facility relocation.

         Exercised outstanding talents in financial leadership for Global Pharmacovigilance inclusive of strategic planning, resource evaluation, and management of a multi-million dollar capital project.

 

Finance Manager, SPRI (2004 to 2005)

• Steered $200M operating budget for NJ-based Discovery Research and early-stage in-licensing organization encompassing financial reporting, operating plan finalization, forecasting, and opportunity/risk identification and management.
• Relied upon to conduct financial analysis and due diligence for acquisition of assets from NeoGenesis.

 

Manager, Capital Planning & Analysis, SPRI (2001 to 2004)

• Led team in full range of capital management including investment justification preparation and analysis, estimate development, cash flow forecasting, and fixed asset management.

         Reliably performed cash flow forecasting, calculation of operational impact analyses, headcount forecasting, growth rate analyses, sensitivity analyses, and NPV calculations.

 

Warner-Lambert Company / Pfizer Inc. Morris Plains, NJ, 1998 to 2000

Tax Manager Transfer Pricing & Economic Analysis

         Meticulously provided financial modeling to support sourcing strategy for Lipitor, Rezulin, Accupril, and Neurontin and built comprehensive multivariate model to determine financial impact of a potential $300M investment in manufacturing assets.

         Prepared transfer pricing documentation required in U.S. and responded to changing global regulations.

         Conducted in-depth economic and financial analyses in support of product pricing structures.

         Contributed to tax due diligence of several realized and unrealized transactions with third parties, including acquisition of Agouron Pharmaceuticals.

 

Prior Background:

 

Senior Tax Consultant, Grant Thornton LLP, New York, NY, 1995 to 1998

Economic Analyst, Transfer Pricing Group, Arthur Andersen LLP, New York, NY, 1993 to 1995

 

 

Master of Business Administration, Emphasis in Finance and International Business

Leonard N. Stern School of Business, New York University, New York, NY, 2001

 

Bachelor of Arts, Political Science, Williams College, Williamstown, MA, 1993